[go: up one dir, main page]

WO1998005684B1 - Oligomeres peptidiques de liaison cmh et procedes d'utilisation - Google Patents

Oligomeres peptidiques de liaison cmh et procedes d'utilisation

Info

Publication number
WO1998005684B1
WO1998005684B1 PCT/US1997/013885 US9713885W WO9805684B1 WO 1998005684 B1 WO1998005684 B1 WO 1998005684B1 US 9713885 W US9713885 W US 9713885W WO 9805684 B1 WO9805684 B1 WO 9805684B1
Authority
WO
WIPO (PCT)
Prior art keywords
residues
oligomer
mhc
molecular linker
flexible molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/013885
Other languages
English (en)
Other versions
WO1998005684A2 (fr
WO1998005684A3 (fr
WO1998005684A9 (fr
Filing date
Publication date
Priority to EP97938153A priority Critical patent/EP0917570A2/fr
Priority to NZ333946A priority patent/NZ333946A/xx
Priority to JP10508219A priority patent/JP2000516808A/ja
Priority to CA002262001A priority patent/CA2262001C/fr
Priority to AU40546/97A priority patent/AU730477B2/en
Application filed filed Critical
Publication of WO1998005684A2 publication Critical patent/WO1998005684A2/fr
Publication of WO1998005684A3 publication Critical patent/WO1998005684A3/fr
Publication of WO1998005684B1 publication Critical patent/WO1998005684B1/fr
Publication of WO1998005684A9 publication Critical patent/WO1998005684A9/fr
Priority to US09/245,487 priority patent/US20020058787A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

On décrit des oligomères comprenant au moins deux peptides de fixation du complexe majeur d'histocompatibilité (CMH), joints par une séquence de liaison moléculaire souple. Ces peptides de fixation du CMH peuvent être des peptides de la classe I ou de la classe II. On décrit également un procédé de clonage orienté, destiné à produire de tels oligomères. On peut utiliser les oligomères décrits, par exemple, en rapport avec des procédés destinés à activer ou inhiber de manière spécifique l'activation de lymphocytes T CD4?+ ou CD8+¿. De tels procédés constituent des approches thérapeutiques au traitement de tumeurs, de désordres auto-immuns, de rejet de greffe allogénique et de réactions allergiques.
PCT/US1997/013885 1996-08-05 1997-08-05 Oligomeres peptidiques de liaison cmh et procedes d'utilisation Ceased WO1998005684A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP97938153A EP0917570A2 (fr) 1996-08-05 1997-08-05 Oligomeres peptidiques de liaison cmh et procedes d'utilisation
NZ333946A NZ333946A (en) 1996-08-05 1997-08-05 MHC binding peptide oligomers
JP10508219A JP2000516808A (ja) 1996-08-05 1997-08-05 Ｍｈｃ結合ペプチドオリゴマーおよび使用方法
CA002262001A CA2262001C (fr) 1996-08-05 1997-08-05 Oligomeres peptidiques de liaison cmh et procedes d'utilisation
AU40546/97A AU730477B2 (en) 1996-08-05 1997-08-05 MHC binding peptide oligomers and methods of use
US09/245,487 US20020058787A1 (en) 1996-08-05 1999-02-05 Mhc binding peptide oligomers and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69216796A 1996-08-05 1996-08-05
US08/692,167 1996-08-05

Publications (4)

Publication Number Publication Date
WO1998005684A2 WO1998005684A2 (fr) 1998-02-12
WO1998005684A3 WO1998005684A3 (fr) 1998-05-14
WO1998005684B1 true WO1998005684B1 (fr) 1998-06-11
WO1998005684A9 WO1998005684A9 (fr) 1998-08-06

Family

ID=24779521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013885 Ceased WO1998005684A2 (fr) 1996-08-05 1997-08-05 Oligomeres peptidiques de liaison cmh et procedes d'utilisation

Country Status (7)

Country Link
US (1) US20020058787A1 (fr)
EP (1) EP0917570A2 (fr)
JP (1) JP2000516808A (fr)
AU (1) AU730477B2 (fr)
CA (1) CA2262001C (fr)
NZ (1) NZ333946A (fr)
WO (1) WO1998005684A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855316B1 (en) * 1994-02-14 2005-02-15 University Of Hawaii Baculovirus produced Plasmodium falciparum vaccine
EP1105414A2 (fr) 1998-07-23 2001-06-13 President And Fellows of Harvard College Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
AU7645700A (en) * 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
US20030100106A1 (en) * 2000-02-08 2003-05-29 Chang Sandra P. Baculovirus produced Plasmodium falciparum vaccine
WO2009003492A1 (fr) 2007-07-03 2009-01-08 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
WO2003029276A2 (fr) 2001-10-03 2003-04-10 President And Fellows Of Harvard College Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
GB2422834B8 (en) * 2005-02-04 2007-01-04 Proimmune Ltd MHC oligomer and method of making the same
AU2006316036B2 (en) 2005-11-17 2011-12-15 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. A compound comprising an autoantigenic peptide and a carrier with a MHC binding motif
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
GB2442048B (en) * 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
GB2440529B (en) * 2006-08-03 2009-05-13 Proimmune Ltd MHC Oligomer, Components Therof, And Methods Of Making The Same
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
WO2009039854A2 (fr) 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US11041013B2 (en) 2008-03-14 2021-06-22 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
WO2010009735A2 (fr) 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
EA023897B1 (ru) * 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
US10179174B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corp. Method for inducing an immune response and formulations thereof
WO2020054126A1 (fr) * 2018-09-14 2020-03-19 国立研究開発法人理化学研究所 Procédé d'introduction d'une substance dans une cellule cible
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
DE69334255D1 (de) * 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür

Similar Documents

Publication Publication Date Title
WO1998005684B1 (fr) Oligomeres peptidiques de liaison cmh et procedes d'utilisation
AU730477B2 (en) MHC binding peptide oligomers and methods of use
KR101902029B1 (ko) 감염성 질환, 자가면역 질환, 동종인자에 대한 면역 반응, 알레르기 질환, 종양, 이식편 거부 및 유전자 요법 또는 유전자 백신접종을 위해 사용되는 바이러스 벡터에 대한 면역 반응의 예방 및/또는 치료에 사용하기 위한 면역원성 펩티드
WO1998005684A9 (fr) Oligomeres peptidiques de liaison cmh et procedes d'utilisation
AU775073C (en) Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
EP0871456B1 (fr) Compositions pharmaceutiques comportant un copolymere peptidique de synthese et servant a la prevention des troubles dus a la reaction greffe contre hote
CA2348956A1 (fr) Procedes immunotherapeutiques utilisant des epitopes de wt-1 et gata-1
NZ281409A (en) Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls
EP0805162A1 (fr) Déterminant peptidique associé à l'immunité
NO309798B1 (no) Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
RU98120519A (ru) Аутоантиген и структурно-родственные ему белки для применения при иммунотерапии аутоиммунных заболеваний
CN113015541A (zh) 具有新氧化还原酶基序的免疫原性肽
EP1870418A1 (fr) Allolimitée peptide spécifiques pour les cellules T
Van der Veen et al. Immune processing of proteolipid protein by subsets of antigen-presenting spleen cells
Cohen et al. Exploring the potential of DNA vaccination
Mackewicz et al. Structural aspects of a protein epitope and their role in the major histocompatibility complex control of T cell responsiveness
Taylor The mechanism of experimental arthritis produced by streptolysin S
Naor et al. Antigenic Entities of the Tumor That Induce Suppressor Cells May Prevent the Potentiation of Coexpressed Immunogenic Entities
Lanzavecchia Antigen processing
Breedveld et al. T-Cell Vaccination—A Prospect
Klein et al. Antigen Processing: A Reevaluation
Martin Specific immunomodulation in multiple sclerosis by altered peptide ligands
HK40038219A (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
HK40038219B (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
HK1185886A (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination